RNS & Investor News

Notice of Annual General Meeting

17 June 2020

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, announces it will hold its Annual General Meeting ("AGM") at 11am on Thursday, 9 July 2020.

Following the UK Government's guidelines imposing mandatory social distancing measures, including restrictions on gatherings of people, the Company's 2020 AGM will be convened with the minimum quorum of shareholders present in order to conduct the business of the meeting. Shareholders wishing to vote on matters of business are urged to do so via the completion of a proxy form. In line with corporate governance best practice, and in order that any proxy votes of those shareholders who are not allowed to attend and vote in person, are fully reflected in the voting on the resolutions, the Chairman of the meeting will direct that voting on all resolutions set out in the notice of meeting will take place by way of a poll. The final poll vote on each resolution will be published after the AGM on the Company's website. The Company will accept electronic copies or photographs of the form of proxy by email to [email protected]

As shareholders will not be able to attend this year's AGM, the Company will allow shareholders to send questions in advance. Appropriate questions should be lodged via the Company's website http://optibiotix.com/contact  before 11am on Tuesday, 7 July 2020 and the Company will aim to  post responses on the their website on the day of the AGM. 

For further information, please contact:

OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via Walbrook below
Cairn Financial Advisers LLP (NOMAD) Tel: 020 7213 0880
Liam Murray / Jo Turner / Ludovico Lazzaretti
finnCap (Broker) Tel: 020 7220 0500
Geoff Nash / Kate Bannatyne (Corporate Finance)
Camille Gochez (Corporate Broking)
Walbrook PR Ltd

Anna Dunphy
Tel: 020 7933 8780 or [email protected]
Mob: 07876 741 001

About OptiBiotix -

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness. 

OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.